Biogen to acquire RayThera for up to $1 billion as J&J shifts focus away from obesity to cancer
Biogen announced an agreement to purchase RayThera for as much as $1 billion, marking the company's second takeover this year. The deal expands Biogen's portfolio into RayThera's pipeline, though specific therapeutic areas were not detailed in the announcement.
Johnson & Johnson said it will not pursue opportunities in the fast‑growing obesity market. Instead, the firm said it will concentrate its resources on disease areas such as cancer, aligning with its broader strategic priorities.
The newsletter also noted that the FDA is reviewing Moderna's seasonal flu vaccine, but no further information about the review’s status or timeline was provided.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about an FDA review of Moderna’s flu shot, J&J’s focus on cancer, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that